For example, the stage II clinical trial for the anti-PD-1 antibody Camrelizumab in combination with the VEGFR inhibitor Apatinib and the chemotherapeutic agent Temozolomide in patients with advanced limb MM noted that the 66.7% objective response rate demonstrated by this combination regimen over the course of treatment exceeds that of any other drug combination explored in the literature. The gene discussed is KDR; the disease is Miyoshi myopathy.